肾细胞癌复发的生物标志物：现状。
Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art.
机构信息
Unit of Urology, Department of Medical, Oral and Biotechnological Sciences, SS. Annunziata Hospital, "G. d'Annunzio University", Chieti, Italy.
Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio" Chieti-Pescara, Via dei Vestini, Campus universitario, 66100, Chieti, Italy.
出版信息
Curr Urol Rep. 2021 Apr 22;22(6):31. doi: 10.1007/s11934-021-01050-0.
Abstract
PURPOSE OF REVIEW
We aim to summarize the current state of art about the possible use of biomarkers for predicting renal cell carcinoma (RCC) recurrence after curative treatment. In addition, we aim to provide a snapshot about the clinical implication of biomarkers use for follow-up planification.
RECENT FINDINGS
A wide variety of biomarkers have been proposed. RCC biomarkers have been individuated in tumoral tissue, blood, and urine. A variety of molecules, including proteins, DNA, and RNA, warrant a good accuracy for RCC recurrence and progression prediction. Their use in prediction models might warrant a better patients' risk stratification. Future prognostic models will probably include a combination of classical features (tumor grade, stage, etc.) and novel biomarkers. Such models might allow a more accurate treatment and follow-up planification.
摘要
目的综述
本文旨在总结目前关于生物标志物在预测根治性治疗后肾细胞癌（RCC）复发中的可能应用的最新研究进展。此外，本文还旨在提供生物标志物在随访计划中的临床应用意义的概述。
最近的发现
已经提出了多种生物标志物。RCC 标志物已在肿瘤组织、血液和尿液中被鉴定出来。包括蛋白质、DNA 和 RNA 在内的多种分子对 RCC 复发和进展的预测具有较好的准确性。它们在预测模型中的应用可能有助于更好地对患者进行风险分层。未来的预后模型可能包括经典特征（肿瘤分级、分期等）和新型生物标志物的组合。这样的模型可能会允许更准确的治疗和随访计划。
相似文献
1
Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art.肾细胞癌复发的生物标志物：现状。
Curr Urol Rep. 2021 Apr 22;22(6):31. doi: 10.1007/s11934-021-01050-0.
2
Prognostic factors and prognostic models for renal cell carcinoma: a literature review.肾细胞癌的预后因素和预后模型：文献综述。
World J Urol. 2018 Dec;36(12):1943-1952. doi: 10.1007/s00345-018-2309-4. Epub 2018 Apr 30.
3
Identification and validation of novel prognostic markers in Renal Cell Carcinoma.肾细胞癌中新型预后标志物的鉴定与验证
Dan Med J. 2017 Oct;64(10).
4
Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma.CD133干性标志物的细胞质表达与透明细胞肾细胞癌的肿瘤侵袭性相关。
Exp Mol Pathol. 2017 Oct;103(2):218-228. doi: 10.1016/j.yexmp.2017.10.001. Epub 2017 Oct 16.
5
HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma.组蛋白去乙酰化酶6作为肾细胞癌患者预后的生物标志物。
Cancer Biomark. 2017;19(2):169-175. doi: 10.3233/CBM-160298.
6
HNF‑4α downregulation promotes tumor migration and invasion by regulating E‑cadherin in renal cell carcinoma.HNF‑4α 下调通过调节肾细胞癌中的 E‑钙黏蛋白促进肿瘤迁移和侵袭。
Oncol Rep. 2019 Sep;42(3):1066-1074. doi: 10.3892/or.2019.7214. Epub 2019 Jun 27.
7
Elevated expression of IFN-inducible CXCR3 ligands predicts poor prognosis in patients with non-metastatic clear-cell renal cell carcinoma.干扰素诱导的CXCR3配体表达升高预示非转移性透明细胞肾细胞癌患者预后不良。
Oncotarget. 2016 Mar 22;7(12):13976-83. doi: 10.18632/oncotarget.7468.
8
Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma.Gankyrin 是一种新型的肾细胞癌患者疾病进展和预后的生物标志物。
EBioMedicine. 2019 Jan;39:255-264. doi: 10.1016/j.ebiom.2018.12.011. Epub 2018 Dec 14.
9
Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.α-烯醇化酶是透明细胞肾细胞癌的一种潜在预后标志物。
Clin Exp Metastasis. 2015 Aug;32(6):531-41. doi: 10.1007/s10585-015-9725-2. Epub 2015 Jun 3.
10
Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up.肿瘤坏死、微血管密度、血管内皮生长因子及缺氧诱导因子-1α在根治性肾切除术后透明细胞肾癌患者长期随访中的预后作用
Int J Immunopathol Pharmacol. 2008 Apr-Jun;21(2):447-55. doi: 10.1177/039463200802100225.
引用本文的文献
1
Survival and treatment of stage IV renal cell carcinoma in academic non-academic medical centers.学术性与非学术性医疗中心中IV期肾细胞癌的生存与治疗
World J Nephrol. 2025 Jun 25;14(2):103923. doi: 10.5527/wjn.v14.i2.103923.
2
Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?早期肾细胞癌：谁需要辅助治疗？
Biomedicines. 2025 Feb 21;13(3):543. doi: 10.3390/biomedicines13030543.
3
Trifecta Outcomes of Robot-Assisted Partial Nephrectomy Using the New Hugo™ RAS System Versus Laparoscopic Partial Nephrectomy.使用新型Hugo™机器人辅助手术系统与腹腔镜部分肾切除术的机器人辅助部分肾切除术的三元组结果
J Clin Med. 2024 Apr 7;13(7):2138. doi: 10.3390/jcm13072138.
4
Use of Droplet Digital Polymerase Chain Reaction to Identify Biomarkers for Differentiation of Benign and Malignant Renal Masses.使用液滴数字聚合酶链反应来鉴定用于区分良性和恶性肾肿块的生物标志物。
Cancers (Basel). 2024 Feb 15;16(4):787. doi: 10.3390/cancers16040787.
5
Biomarkers in renal cell carcinoma and their targeted therapies: a review.肾细胞癌中的生物标志物及其靶向治疗：综述
Explor Target Antitumor Ther. 2023;4(5):941-961. doi: 10.37349/etat.2023.00175. Epub 2023 Oct 25.
6
Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic.肾细胞癌的治疗管理：有前途的生物标志物及面临的临床转化挑战。
Clin Cancer Res. 2024 Feb 16;30(4):663-672. doi: 10.1158/1078-0432.CCR-23-1892.
7
Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker.肾细胞癌中肌酐与胱抑素 C 比值：一种临床实用的预后因素和肌肉减少症生物标志物。
Oncologist. 2023 Dec 11;28(12):e1219-e1229. doi: 10.1093/oncolo/oyad218.
8
Establishment and validation of a prognostic nomogram for patients with renal cell carcinoma based on SEER and TCGA database.基于SEER和TCGA数据库的肾细胞癌患者预后列线图的建立与验证
Transl Cancer Res. 2023 Jun 30;12(6):1411-1421. doi: 10.21037/tcr-22-2692. Epub 2023 Jun 9.
9
Serum extracellular vesicles derived hsa-miR-320d as an indicator for progression of clear cell renal cell carcinoma.血清细胞外囊泡衍生的hsa-miR-320d作为透明细胞肾细胞癌进展的指标。
Discov Oncol. 2023 Jun 28;14(1):114. doi: 10.1007/s12672-023-00730-2.
10
Chasing the Role of miRNAs in RCC: From Free-Circulating to Extracellular-Vesicle-Derived Biomarkers.追寻微小RNA在肾细胞癌中的作用：从游离循环生物标志物到细胞外囊泡衍生生物标志物
Biology (Basel). 2023 Jun 17;12(6):877. doi: 10.3390/biology12060877.
本文引用的文献
1
Altered Tissue and Plasma Levels of Fibroblast Activation Protein-α (FAP) in Renal Tumours.肾肿瘤中组织及血浆成纤维细胞激活蛋白-α（FAP）水平的改变
Cancers (Basel). 2020 Nov 16;12(11):3393. doi: 10.3390/cancers12113393.
2
Computed tomography features predicting aggressiveness of malignant parenchymal renal tumors suitable for partial nephrectomy.预测适合部分肾切除术的肾实质恶性肿瘤侵袭性的计算机断层扫描特征。
Minerva Urol Nephrol. 2021 Feb;73(1):17-31. doi: 10.23736/S2724-6051.20.04073-4. Epub 2020 Nov 17.
3
Liquid Biopsies in Renal Cell Carcinoma-Recent Advances and Promising New Technologies for the Early Detection of Metastatic Disease.肾细胞癌中的液体活检——转移性疾病早期检测的最新进展和有前景的新技术
Front Oncol. 2020 Oct 28;10:582843. doi: 10.3389/fonc.2020.582843. eCollection 2020.
4
The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.组织学亚型对肾细胞癌患者手术后复发的发生率、时间和模式的影响——来自 RECUR 联盟的结果。
Eur Urol Oncol. 2021 Jun;4(3):473-482. doi: 10.1016/j.euo.2020.09.005. Epub 2020 Oct 24.
5
Circulating Non-coding RNAs in Renal Cell Carcinoma-Pathogenesis and Potential Implications as Clinical Biomarkers.肾细胞癌中的循环非编码RNA——发病机制及作为临床生物标志物的潜在意义
Front Cell Dev Biol. 2020 Sep 15;8:828. doi: 10.3389/fcell.2020.00828. eCollection 2020.
6
A Meta-Analysis of Glasgow Prognostic Score and Modified Glasgow Prognostic Score as Biomarkers for Predicting Survival Outcome in Renal Cell Carcinoma.格拉斯哥预后评分和改良格拉斯哥预后评分作为预测肾细胞癌生存结局生物标志物的Meta分析
Front Oncol. 2020 Sep 17;10:1541. doi: 10.3389/fonc.2020.01541. eCollection 2020.
7
TYROBP is a potential prognostic biomarker of clear cell renal cell carcinoma.TYROBP 是透明细胞肾细胞癌的一个潜在预后生物标志物。
FEBS Open Bio. 2020 Dec;10(12):2588-2604. doi: 10.1002/2211-5463.12993. Epub 2020 Oct 31.
8
Active surveillance for small renal masses in elderly patients does not increase overall mortality rates compared to primary intervention: a propensity score weighted analysis.与初次干预相比，对老年患者小肾脏肿块进行主动监测并不会增加总体死亡率：一项倾向评分加权分析。
Minerva Urol Nephrol. 2021 Dec;73(6):781-788. doi: 10.23736/S2724-6051.20.03785-6. Epub 2020 Sep 29.
9
Impact of positive surgical margins on survival after partial nephrectomy in localized kidney cancer: analysis of the National Cancer Database.局部肾细胞癌肾部分切除术后切缘阳性对生存的影响：国家癌症数据库分析。
Minerva Urol Nephrol. 2021 Apr;73(2):233-244. doi: 10.23736/S2724-6051.20.03728-5. Epub 2020 Aug 4.
10
Triggers for delayed intervention in patients with small renal masses undergoing active surveillance: a systematic review.主动监测中小肾肿瘤患者延迟干预的触发因素：系统评价。
Minerva Urol Nefrol. 2020 Aug;72(4):389-407. doi: 10.23736/S0393-2249.20.03870-9.
Zotero 插件